Alto Neuroscience (ANRO) Research & Development (2023 - 2026)
Alto Neuroscience's Research & Development came in at $22.11 million for Q2 2026, up 68.5% from $13.12 million a year earlier and up 8.9% from the prior quarter.
Powered by 
Analysis
Alto Neuroscience (ANRO) Research & Development (2023 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Alto Neuroscience reported Research & Development of $64.92 million, up 38.3% year-over-year; for FY2025, it was $45.62 million, down 2.9% from FY2024.
- Going back by year, Research & Development was $47 million in FY2024 (+55.1%) and $30.29 million in FY2023.
- The Q2 2026 figure represents the highest quarterly Research & Development in data going back to Q1 2023.
- Year-over-year, Research & Development has increased for three consecutive quarters, with growth averaging 29.9% over the last eight quarters.
- The fastest year-over-year change in Research & Development over five years came in Q1 2026 (growth of 103.5%), and the weakest in Q3 2025 (a decline of 19.4%).
- Business Quant data shows ANRO's Research & Development at $20.29 million (Q1 2026), $12 million (Q4 2025) and $10.53 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,130.22 Bn | 1,098.81 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 613.62 Bn | 532.15 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 501.46 Bn | 474.57 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.84 Bn | 321.22 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.85 Bn | 261.84 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.66 Bn | 235.34 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 235.39 Bn | 190.79 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 190.66 Bn | 164.86 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 169.57 Bn | 116.22 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Alto Neuroscience | 1.03 Bn | 208.71 Mn | - | 22.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.11 Mn |
| Mar 31, 2026 | 20.29 Mn |
| Dec 31, 2025 | 12.00 Mn |
| Sep 30, 2025 | 10.53 Mn |
| Jun 30, 2025 | 13.12 Mn |
| Mar 31, 2025 | 9.97 Mn |
| Dec 31, 2024 | 10.80 Mn |
| Sep 30, 2024 | 13.06 Mn |
| Jun 30, 2024 | 13.18 Mn |
| Mar 31, 2024 | 9.95 Mn |
| Dec 31, 2023 | 9.64 Mn |
| Sep 30, 2023 | 7.97 Mn |
| Jun 30, 2023 | 7.07 Mn |
| Mar 31, 2023 | 5.61 Mn |
API Access
Alto Neuroscience Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ANRO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ANRO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ANRO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();